← Back to Search

Peptide Hormone

Oxytocin for Alcoholism and Healthy Controls

Phase 2

Waitlist Available

Led By Tiffany Love, PhD

Research Sponsored by University of Utah

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18-45 years of age at the time of screening

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from week 1, day 1, scan 1 and scan 2 (approximately 1-4 weeks after scan 1)

Awards & highlights

Study Summary

This trial will look at how oxytocin affects the brain's response to social and non-social activities.

Who is the study for?

This study is for people aged 18-45 who can handle an MRI scan without issues like metal implants or claustrophobia. It's not for those with serious medical conditions, pregnant/nursing women, or anyone allergic to oxytocin. Participants shouldn't be on certain medications including antipsychotics and antidepressants.Check my eligibility

What is being tested?

The trial tests how a nasal spray of oxytocin versus a placebo affects brain activity related to motivation in both social and non-social contexts, using fMRI scans to observe changes.See study design

What are the potential side effects?

Oxytocin may cause side effects such as irritation at the site of administration, headaches, nausea, changes in heart rate or blood pressure, emotional changes, and possibly allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 45 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from week 1, day 1, scan 1 and scan 2 (approximately 1-4 weeks after scan 1)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from week 1, day 1, scan 1 and scan 2 (approximately 1-4 weeks after scan 1)

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from week 1, day 1, scan 1 and scan 2 (approximately 1-4 weeks after scan 1) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Functional Magnetic Resonance Imaging (fMRI) Data: Change in BOLD Activity Between Placebo and Oxytocin Treatment. AUD vs Controls

Oxytocin

Functional Magnetic Resonance Imaging (fMRI) Data: Change in BOLD Activity Between Placebo and Oxytocin Treatment: Control group

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: OxytocinExperimental Treatment1 Intervention

Each participant will be studied using fMRI following self-administration of oxytocin.

Group II: PlaceboPlacebo Group1 Intervention

Each participant will be studied using fMRI following self-administration of placebo.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Oxytocin

2016

Completed Phase 4

~2340

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor

1,099 Previous Clinical Trials

1,778,634 Total Patients Enrolled

Tiffany Love, PhD5.0373 ReviewsPrincipal Investigator - University of Utah

Intermountain Medical Center, Saint Mark's Hospital

Medical School - University of Utah, Doctor of Medicine

University of Utah, Residency in Obstetrics and Gynecology

5Patient Review

They were extremely detail-oriented and patient in answering all of my questions. I would recommend this doctor to anybody seeking a high-quality medical professional.